| Literature DB >> 33287827 |
Muqing Wang1, Xubin Jing1, Weihua Cao2, Yicheng Zeng1, Chaofen Wu1, Weilong Zeng1, Wenxia Chen1, Xi Hu1, Yanna Zhou1, Xianbin Cai3.
Abstract
BACKGROUND: Patients suffering from gastrointestinal cancer comprise a large group receiving home hospice care in China, however, little is known about the prediction of their survival time. This study aimed to develop a gastrointestinal cancer-specific non-lab nomogram predicting survival time in home-based hospice.Entities:
Keywords: Gastrointestinal cancer; Home-based hospice; LASSO; Nomogram; Prognosis of survival
Mesh:
Year: 2020 PMID: 33287827 PMCID: PMC7722330 DOI: 10.1186/s12904-020-00690-2
Source DB: PubMed Journal: BMC Palliat Care ISSN: 1472-684X Impact factor: 3.234
Fig. 1The survival curve for patients with gastrointestinal cancer in home palliative care
Patient characteristics between the training and testing dataset
| Patient characteristic | Training set | Testing set | P | Patient characteristic | Training set | Testing set | P |
|---|---|---|---|---|---|---|---|
| No. of patients | 1214 | 404 | Surgery (%) | 0.792 | |||
| Survival time (median [IQR]), days | 35.00 [17.00, 66.00] | 34.00 [18.00, 68.00] | 0.844 | N | 680 (56.0) | 230 (56.9) | |
| Sex (%) | 0.037 | Y | 534 (44.0) | 174 (43.1) | |||
| Female | 378 (31.1) | 103 (25.5) | Chemotherapy (%) | 0.946 | |||
| Male | 836 (68.9) | 301 (74.5) | N | 777 (64.0) | 260 (64.4) | ||
| Age (%) | 0.103 | Y | 437 (36.0) | 144 (35.6) | |||
| < 60 years | 527 (43.4) | 156 (38.6) | Radiotherapy (%) | 0.038 | |||
| ≥ 60 years | 687 (56.6) | 248 (61.4) | N | 1085 (89.4) | 345 (85.4) | ||
| Area of residence (%) | 0.083 | Y | 129 (10.6) | 59 (14.6) | |||
| Rural | 379 (31.2) | 107 (26.5) | Duration of pain (%) | 0.247 | |||
| Urban | 835 (68.8) | 297 (73.5) | < 1 month | 259 (21.3) | 102 (25.2) | ||
| Education (%) | 0.863 | 1–6 months | 831 (68.5) | 260 (64.4) | |||
| Illiteracy | 163 (13.4) | 61 (15.1) | 6–12 months | 99 (8.2) | 30 (7.4) | ||
| Primary school | 589 (48.5) | 199 (49.3) | > 12 months | 25 (2.1) | 12 (3.0) | ||
| Middle school | 292 (24.1) | 89 (22.0) | Previous analgesic treatment (%) | 0.642 | |||
| High school | 133 (11.0) | 42 (10.4) | None | 349 (28.7) | 116 (28.7) | ||
| High school above | 37 (3.0) | 13 (3.2) | NSAIDs | 123 (10.1) | 50 (12.4) | ||
| Awareness of the disease (%) | 0.121 | Weak Opioids | 373 (30.7) | 119 (29.5) | |||
| Full understanding | 675 (55.6) | 212 (52.5) | Strong Opioids | 369 (30.4) | 119 (29.5) | ||
| Partial understanding | 191 (15.7) | 55 (13.6) | Effect (%) | 0.995 | |||
| Complete ignorance | 348 (28.7) | 137 (33.9) | None | 280 (23.1) | 94 (23.3) | ||
| Metastasis (%) | 0.468 | Bad | 163 (13.4) | 54 (13.4) | |||
| N | 260 (21.4) | 79 (19.6) | Average | 618 (50.9) | 207 (51.2) | ||
| Y | 954 (78.6) | 325 (80.4) | Satisfied | 153 (12.6) | 49 (12.1) | ||
| Hypertension (%) | 0.517 | Vomiting (%) | 0.02 | ||||
| N | 1031 (84.9) | 337 (83.4) | N | 825 (68.0) | 300 (74.3) | ||
| Y | 183 (15.1) | 67 (16.6) | Y | 389 (32.0) | 104 (25.7) | ||
| Diabetes (%) | 0.231 | Abdominal distention (%) | 0.684 | ||||
| N | 1108 (91.3) | 360 (89.1) | N | 808 (66.6) | 274 (67.8) | ||
| Y | 106 (8.7) | 44 (10.9) | Y | 406 (33.4) | 130 (32.2) | ||
| Smoke (%) | 0.978 | Tachypnea (%) | 0.352 | ||||
| N | 1025 (84.4) | 342 (84.7) | N | 937 (77.2) | 302 (74.8) | ||
| Y | 189 (15.6) | 62 (15.3) | Y | 277 (22.8) | 102 (25.2) | ||
| Drink (%) | 0.83 | Edema (%) | 0.599 | ||||
| N | 1112 (91.6) | 368 (91.1) | N | 969 (79.8) | 328 (81.2) | ||
| Y | 102 (8.4) | 36 (8.9) | Y | 245 (20.2) | 76 (18.8) | ||
| Constipation (%) | 0.731 | NRS (%) | 0.152 | ||||
| N | 690 (56.8) | 225 (55.7) | 0–3 | 126 (10.4) | 55 (13.6) | ||
| Y | 524 (43.2) | 179 (44.3) | 4–6 | 664 (54.7) | 205 (50.7) | ||
| Weight loss (%) | 0.201 | 7–10 | 424 (34.9) | 144 (35.6) | |||
| N | 101 (8.3) | 25 (6.2) | KPS (%) | 0.313 | |||
| Y | 1113 (91.7) | 379 (93.8) | ≤30 | 375 (30.9) | 141 (34.9) | ||
| Insomnia (%) | 0.062 | 40 | 531 (43.7) | 169 (41.8) | |||
| N | 597 (49.2) | 221 (54.7) | ≥50 | 308 (25.4) | 94 (23.3) | ||
| Y | 617 (50.8) | 183 (45.3) | QOL (%) | 0.416 | |||
| Anorexia (%) | 0.684 | ≤30 | 450 (37.1) | 140 (34.7) | |||
| N | 168 (13.8) | 52 (12.9) | > 30 | 764 (62.9) | 264 (65.3) | ||
| Y | 1046 (86.2) | 352 (87.1) | Status (%) | 0.655 | |||
| Nausea (%) | 0.328 | Censored | 110 (9.1) | 33 (8.2) | |||
| N | 835 (68.8) | 289 (71.5) | Dead | 1104 (90.9) | 371 (91.8) | ||
| Y | 379 (31.2) | 115 (28.5) |
Fig. 2Identification of predictors using the Lasso Cox regression. a Selection of tuning parameter (λ) in the LASSO regression using 10-fold cross-validation. The vertical line was plotted using the minimum criteria and the one standard error of the minimum criteria. b LASSO coefficient profiles of variables. Each colored line represents a variable in the model. With increases in λ, the coefficient of each variable decreased. At the optimal values log (λ) = − 2.375, five variables (KPS, abdominal distention, edema, QOL, and duration of pain) with a nonzero coefficient were selected
The result of Lasso Cox regression
| Variable | β | HR | 95%CI | Waldχ2 | P |
|---|---|---|---|---|---|
| Duration of pain | |||||
| 1–6 months | −0.185 | 0.831 | 0.716–0.965 | −2.423 | 0.015 |
| 6–12 months | −0.385 | 0.681 | 0.534–0.867 | −3.111 | 0.002 |
| > 12 months | −0.570 | 0.566 | 0.357–0.897 | −2.422 | 0.015 |
| Abdominal distention | |||||
| Y | 0.388 | 1.475 | 1.291–1.685 | 5.714 | 1.11e-08 |
| Edema | |||||
| Y | 0.340 | 1.405 | 1.205–1.638 | 4.336 | 1.45e-05 |
| KPS | |||||
| 40 | −0.490 | 0.613 | 0.530–0.708 | −6.618 | 3.64e-11 |
| ≥ 50 | −0.736 | 0.479 | 0.398–0.576 | −7.815 | 5.50e-15 |
| QOL | |||||
| >30 | −0.201 | 0.818 | 0.711–0.940 | −2.834 | 0.005 |
Fig. 3Nomogram predicting the 30-day and 60-day survival probability for patients with gastrointestinal cancer in home palliative care
Fig. 4Receiver operating characteristic (ROC) curve analysis for the nomogram in the training dataset
Fig. 5Receiver operating characteristic (ROC) curve analysis for the nomogram in the testing dataset
Fig. 6Calibration curves for predicting (a) 30-day and (b) 60-day overall survival in the training dataset
Fig. 7Calibration curves for predicting (a) 30-day and (b) 60-day overall survival in the testing dataset